Herantis Pharma

Herantis Pharma

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Herantis Pharma - A closer look at the 12-month Parkinson’s data

16 september 2020

Top-line data for CDNF presented without surprises
Primary safety endpoint met
Plans for next study to determine efficacy in the pipeline
Treatment-related serious adverse events resolved
Management provided further details yesterday in a webcast on the initial 12-month data of the first-in-human clinical trial of CDNF, with emphasis placed on the safety and tolerability. Safety data remain encouraging, and importantly, the two treatment-related serious adverse events that led to two participants withdrawing from the trial in the first 6-month main study were not replicated in the subsequent 6-month extension study. These two events were described as being infusion-procedure related infections, and following the mitigation strategies put in place by Renishaw (the intra-cranial delivery system provider), the final 87 infusions were conducted without adverse events. Importantly, no dose-limiting toxicities related to CDNF itself were recorded.

Suggestions of an efficacy signal persist
As the study was small (n=17), and carried out in a sub-optimal patient group with moderately advanced disease, management rightly tempered expectations for any meaningful efficacy read-out. Nonetheless, a couple of encouraging individual cases with responses on clinical assessment by UPDRS and DAT PET imaging were highlighted, including a sustained DAT PET result in one of the “high responders” from the 6-month data presentation. Overall, a lack of obvious deterioration at the group-level coupled with signals of efficacy in certain patients gives reason to look forward to the next clinical study where efficacy can be gauged with greater confidence.

More clinical data to come before the next study is finalised
We view yesterday’s webcast as largely in line with the previously reported data and without any major surprises, so we leave our estimates unchanged. We look forward to the remaining data from secondary endpoints yet to be analysed, and the DAT PET imaging from the follow-up phase of the study at 19 months, along with the design of the next clinical study for CDNF to be finalized by year-end.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2020-10-19 Nilörngruppen - Delivering on cost control Nilörngruppen Analys
2020-10-16 Fortnox - ESG profile Fortnox Analys
2020-10-16 Formpipe - ESG profile Formpipe Analys
2020-10-16 SinterCast - 2019 dividend back on the agenda SinterCast Analys
2020-10-15 Nilörngruppen - Still tough, but we see light in ... Nilörngruppen Analys
2020-10-15 Doro - Announces its third M&A post summer Doro Analys
2020-10-15 Maha Energy - Guidance update reflects soft end t... Maha Energy Analys
2020-10-15 Vitec - Solid Q3’20 report from Vitec Vitec Analys
2020-10-15 GreenMobility - Getting bigger and bigger GreenMobility Analys
2020-10-14 Svedbergs - Q3 to show continued cost control Svedbergs Analys
2020-10-14 Fiskars Group - Reinstates guidance for increased... Fiskars Group Analys
2020-10-14 Maha Energy - Some operational hiccups in Q3 Maha Energy Analys
2020-10-14 Tethys Oil - Producing above quota Tethys Oil Analys
2020-10-13 Handicare - Improved Stairlift demand drives stro... Handicare Analys
2020-10-13 SinterCast - 2019 dividend back on the agenda SinterCast Analys
2020-10-13 Handicare - Strong Q3’20 as demand recovers for S... Handicare Analys
2020-10-12 Vestjysk Bank - ESG profile Vestjysk Bank Analys
2020-10-09 Pricer - Pre-released Q3 EBIT well above our fore... Pricer Analys
2020-10-08 Addtech - A tough quarter and challenging comps Addtech Analys
2020-10-08 Lagercrantz - We expect another mild quarter Lagercrantz Analys